ClinicalTrials.gg
CompletedNCT03365375MBSRUpdated Jan 24, 2024Results posted

Mindfulness-Based Stress Reduction for Adults With Low-Risk Chest Pain Associated With Anxiety

An interventional study of MBSR Referral and Usual Care Referral in Chest Pain, Anxiety and Mindfulness, sponsored by Indiana University. Completed at 1 site in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2024-01-24.

Sponsored by Indiana University · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
28
Allocation
Non-randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

This Emergency Department based study investigates the feasibility and effectiveness of a mindfulness based stress reduction (MBSR) training program referral for patients with chest pain at low risk for acute coronary syndrome but associated with anxiety. Outcomes assessed for eligible patients randomized to MBSR vs. usual care include mental health (longitudinal Generalized Anxiety Disorder - 7 (GAD-7) scores), quality of life (PROMIS Global Short Form), and ED resource utilization (return Emergency Department (ED) visits).

Read the detailed description

To determine the effect of an MBSR training program for patients with low-risk chest pain associated with anxiety on mental health (longitudinal GAD-7 scores, quality of life (PROMIS Global Short Form), and ED resource utilization (return ED visits). The working hypothesis is that early referral to MBSR will help patients better regulate their thoughts, feelings, and bodily sensations related to their anxiety symptoms and have a significant positive effect on patient-centered outcomes such as mental health, quality of life as well as decreased ED resource utilization. To this end the investigators will randomize patients identified via a two step process (HEART Score \<4 and GAD-7 score > 9 to usual care referrals versus MBSR. The investigators will then follow these participants for outcomes including change in GAD-7 scores, PROMIS Global Short Form, ED utilization among other outcomes at 6 weeks, 3 months, 6 months, and 1 year.

02

Conditions studied

  • Chest Pain
  • Anxiety
  • Mindfulness

Keywords

  • Chest Pain
  • Anxiety
  • Mindfulness
  • Emergency Service, Hospital
03

In context

Chest Pain

388 studies on the registry are indexed under Chest Pain; 64 are open to participants now.

This study's enrollment of 28 is below the median of 129 across 204 interventional studies indexed under Chest Pain.

Browse Chest Pain studies →

Lead sponsor

Indiana University is the lead sponsor of 986 studies on the registry; 198 are open to participants now.

Of its 148 completed or terminated interventional studies of FDA-regulated products, 118 (80%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Chief complaint of chest pain
  • HEART Score of 0-3 indicating Major Adverse Cardiac Events (MACE) risk equivalent to ≤2%
  • GAD-7 score > or = 10

Exclusion criteria

Exclusion Criteria:

  • Age \<18 or ≥ 71
  • Chief complaint of anxiety, panic, or similar
  • Prior personal acute coronary syndrome (ACS) history (known at time of provider interview)
  • Previous enrollment in the study
  • Traumatic injury to the chest
  • Suicidal ideation or active psychosis or behavioral issues requiring psychiatric monitoring
  • Hemodynamic instability
  • Non-English speaking
  • Potential issues affecting follow up: Prisoners, homeless patients, out-of-town residences
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
28 participants (actual)

Study arms

  • Active comparator
    Usual Care Referral

    Subjects will be referred for primary care provider (PCP) follow up and/or to psychiatry for further management and treatment of elevated anxiety levels according to standard of care.

    Other: Usual Care Referral

  • Experimental
    MBSR Referral

    Referral to a local mindfulness-based stress reduction course in addition to referral to their PCP.

    Behavioral: MBSR Referral · Other: Usual Care Referral

Interventions

  • BehavioralMBSR Referral

    Referral for mindfulness-based stress reduction (MBSR), a structured meditation training program consisting of 8 weekly group sessions.

    Also known as: MBSR

  • OtherUsual Care Referral

    Referral to PCP or Psychiatry

06

What researchers measure

Primary outcomes

  1. Mean Difference in Generalized Anxiety Disorder -7 (GAD-7)

    Difference in GAD-7 score at enrollment compared to assessment at 3 months. Anxiety Severity by total score. Range 0-21. Mild 5-9; Moderate (10-14); Severe \> 15

    Time frame: Measured at 3 months

Secondary outcomes

  1. Generalized Anxiety Disorder -7

    Anxiety Severity by total score. Range 0-21. Mild 5-9; Moderate (10-14); Severe \> 15

    Time frame: Measured at 45 days, 6 months, and 12 months

  2. ED Utilization

    Return visits to the Emergency Department

    Time frame: Measured at 45 days, 3 months, 6 months, and 12 months

  3. Patient-Reported Outcomes Measurement Information System (PROMIS) Global Short Form

    quality of life

    Time frame: Measured at 45 days, 3 months, 6 months, and 12 months

  4. Cognitive and Affective Mindfulness Scale - Revised

    12-item measure (each scored 1-4) with total of 48. A higher score is consistent with greater mindfulness qualities.

    Time frame: Measured at 45 days, 3 months, 6 months, and 12 months

  5. Toronto Mindfulness Scale

    13-item state-mindfulness measure that has two sub-scales: Curiosity, 6 items, subscale score ranging from 0-24, and Decentering, 7 items, with a subscale score ranging from 0-28.

    Time frame: Measured at 45 days, 3 months, 6 months, and 12 months

Other outcomes

  1. Patient Health Questionnaire - 8 (Depression)

    Measure of current depression: None - Minimal depression (0 to 4), Mild depression (5 to 9), Moderate depression (10 to 14), Moderately severe depression (15 to 19), Severe depression (20 to 24)

    Time frame: Measured at 45 days, 3 months, 6 months, and 12 months

  2. Patient Health Questionnaire - 15 (Physical Symptoms)

    Somatic symptom severity: Minimal 0-4, Low 5-9, Medium 10-14, High 15-30

    Time frame: Measured at 45 days, 3 months, 6 months, and 12 months

  3. Healthcare Utilization

    Visits to care professionals other then the ED

    Time frame: Measured at 45 days, 3 months, 6 months, and 12 months

  4. PTSD Screener

    4 item measure (each scored 0 or 1). Higher score associated with higher likelihood of a PTSD.

    Time frame: Measured at 45 days, 3 months, 6 months, and 12 months

  5. Panic Screener

    5 item measure (each scored 0 or 1). Higher score associated with higher likelihood of a panic disorder.

    Time frame: Measured at 45 days, 3 months, 6 months, and 12 months

  6. Social Anxiety Screener

    3 item measure (each scored 1-4) with total possible score of 12. Higher score associated with higher social anxiety

    Time frame: Measured at 45 days, 3 months, 6 months, and 12 months

07

Results

Posted Jan 24, 2024

Participant flow

We screened patients who presented to the Emergency Department (ED) with chest pain. We assessed their risk for major adverse cardiac events (MACE) using the HEART score and for anxiety with the GAD-7. Enrolled subjects were assigned to either arm depending upon enrollment period. In the 8 weeks prior to the MBSR course commencement all subjects enrolled were assigned to Arm 2: MBSR. This period was immediately followed by 8 weeks of enrollment in Arm 1: Standard Referral.

Participant flow — Overall Study
MilestoneUsual Care ReferralMBSR Referral
Started1414
Completed149
Not completed05
Withdrew: Withdrawal by subject01
Withdrew: Lost to follow-up04

Outcome measures

PrimaryMean Difference in Generalized Anxiety Disorder -7 (GAD-7)

Difference in GAD-7 score at enrollment compared to assessment at 3 months. Anxiety Severity by total score. Range 0-21. Mild 5-9; Moderate (10-14); Severe \> 15

Time frame:
Measured at 3 months
Reported as:
Mean · score on a scale
Mean Difference in Generalized Anxiety Disorder -7 (GAD-7)
score on a scaleUsual Care ReferralMBSR Referral
Mean Difference in Generalized Anxiety Disorder -7 (GAD-7)5.3 ± 5.43.2 ± 8.1
Statistical analysis
  • Usual Care Referral vs MBSR Referral · t-test, 2 sided · p = 0.82 · Mean difference (final values): 3
SecondaryGeneralized Anxiety Disorder -7

Anxiety Severity by total score. Range 0-21. Mild 5-9; Moderate (10-14); Severe \> 15

Time frame:
Measured at 45 days, 6 months, and 12 months

Results for this outcome have not been posted.

SecondaryED Utilization

Return visits to the Emergency Department

Time frame:
Measured at 45 days, 3 months, 6 months, and 12 months

Results for this outcome have not been posted.

SecondaryPatient-Reported Outcomes Measurement Information System (PROMIS) Global Short Form

quality of life

Time frame:
Measured at 45 days, 3 months, 6 months, and 12 months

Results for this outcome have not been posted.

SecondaryCognitive and Affective Mindfulness Scale - Revised

12-item measure (each scored 1-4) with total of 48. A higher score is consistent with greater mindfulness qualities.

Time frame:
Measured at 45 days, 3 months, 6 months, and 12 months

Results for this outcome have not been posted.

SecondaryToronto Mindfulness Scale

13-item state-mindfulness measure that has two sub-scales: Curiosity, 6 items, subscale score ranging from 0-24, and Decentering, 7 items, with a subscale score ranging from 0-28.

Time frame:
Measured at 45 days, 3 months, 6 months, and 12 months

Results for this outcome have not been posted.

Other pre-specifiedPatient Health Questionnaire - 8 (Depression)

Measure of current depression: None - Minimal depression (0 to 4), Mild depression (5 to 9), Moderate depression (10 to 14), Moderately severe depression (15 to 19), Severe depression (20 to 24)

Time frame:
Measured at 45 days, 3 months, 6 months, and 12 months

Results for this outcome have not been posted.

Other pre-specifiedPatient Health Questionnaire - 15 (Physical Symptoms)

Somatic symptom severity: Minimal 0-4, Low 5-9, Medium 10-14, High 15-30

Time frame:
Measured at 45 days, 3 months, 6 months, and 12 months

Results for this outcome have not been posted.

Other pre-specifiedHealthcare Utilization

Visits to care professionals other then the ED

Time frame:
Measured at 45 days, 3 months, 6 months, and 12 months

Results for this outcome have not been posted.

Other pre-specifiedPTSD Screener

4 item measure (each scored 0 or 1). Higher score associated with higher likelihood of a PTSD.

Time frame:
Measured at 45 days, 3 months, 6 months, and 12 months

Results for this outcome have not been posted.

Other pre-specifiedPanic Screener

5 item measure (each scored 0 or 1). Higher score associated with higher likelihood of a panic disorder.

Time frame:
Measured at 45 days, 3 months, 6 months, and 12 months

Results for this outcome have not been posted.

Other pre-specifiedSocial Anxiety Screener

3 item measure (each scored 1-4) with total possible score of 12. Higher score associated with higher social anxiety

Time frame:
Measured at 45 days, 3 months, 6 months, and 12 months

Results for this outcome have not been posted.

Adverse events

Collected over 12 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Usual Care Referral0/14 (0%)0/14 (0%)0/14 (0%)
MBSR Referral0/14 (0%)0/14 (0%)0/14 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(years)Usual Care ReferralMBSR ReferralTotal
Mean43.3 ± 9.338.9 ± 11.941.2 ± 11.1
Sex: Female, Male
Sex: Female, Male(Participants)Usual Care ReferralMBSR ReferralTotal
Female11920
Male358
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Usual Care ReferralMBSR ReferralTotal
Hispanic or Latino123
Not Hispanic or Latino131225
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Usual Care ReferralMBSR ReferralTotal
American Indian or Alaska Native101
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American7714
White6511
More than one race000
Unknown or Not Reported022
GAD-7 at enrollment
GAD-7 at enrollment(units on a scale)Usual Care ReferralMBSR ReferralTotal
Mean15.9 ± 4.414.9 ± 3.115.3 ± 3.6
08

Study locations

1 site
  • IU Health Methodist Hospital
    Indianapolis, Indiana 46202, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Deidentified data from the clinical study report and the study protocol will be shared upon request.

Supporting information: Study protocol, Clinical study report

Time frame: Data will be available for 5 years after study completion date.

Access criteria: email PI at pmusey@iu.edu

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2018 to primary completion in Aug 2019, 18 months.

Results were first posted in Jan 2024, 4 years 5 months after primary completion.

Of 84 non-industry interventional studies with no phase under Chest Pain, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 43. This study's 18 months is below that.

Counting every sponsor, half of 86 studies reached it within 23 months; a quarter within 9 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 27, 2017
First posted
Dec 7, 2017
StartActual
Jan 28, 2018
Primary completionActual
Aug 1, 2019
CompletionActual
Sep 1, 2020
Results first posted
Jan 24, 2024
Last update
Jan 24, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 24, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03365375
Lead sponsor
Indiana University
Collaborators
Indiana University Health
Responsible party
Paul Musey (Assistant Professor of Emergency Medicine, Indiana University) — Principal investigator
First posted
Dec 7, 2017
Start date
Jan 28, 2018
Primary completion
Aug 1, 2019
Completion
Sep 1, 2020
Results posted
Jan 24, 2024
Last update
Jan 24, 2024

Study contacts

Paul I Musey, MD, MS
principal investigator · Indiana University School of Medicine, Department of Emergency Medicine

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion